Today: 18 July 2026
Browse Category

Biotechnology 15 October 2025 - 19 October 2025

CRISPR Therapeutics Stock Explodes on Gene-Editing Breakthroughs – Analysts See 35% Upside

CRISPR Therapeutics Stock Explodes on Gene-Editing Breakthroughs – Analysts See 35% Upside

CRISPR Therapeutics has reported a string of positive R&D updates in recent weeks. On October 10, 2025, CRSP presented preclinical results for CTX460, its SyNTase-based therapy for alpha-1 antitrypsin deficiency. The data – highlighted at the ESGCT conference – showed that a single dose of CTX460 delivered by lipid nanoparticles corrected the disease-causing mutation in >90% of liver cells and boosted functional AAT protein ~5-fold in animal models globenewswire.com. “The preclinical results demonstrate the potential of CTX460, developed using our novel SyNTase editing platform, to correct the mutation with precision and efficiency,” said CRISPR CMO Dr. Naimish Patel globenewswire.com. These findings suggest a “best-in-class” approach to addressing AATD’s underlying cause, and the company aims to start a first-in-human trial in mid-2026.
19 October 2025
···
GRAIL (GRAL) Stock Skyrockets on Samsung’s $110M Bet and Cancer-Screening Breakthrough

GRAIL (GRAL) Stock Skyrockets on Samsung’s $110M Bet and Cancer-Screening Breakthrough

GRAIL’s logo at company headquarters. The Menlo Park biotech specializes in blood-based early cancer screening through its Galleri test news.samsung.com tradingview.com. GRAIL, Inc. is focused on early cancer detection – its mission is “to detect cancer early when it can be cured” news.samsung.com. The company’s Galleri test analyzes tumor DNA in blood to screen for dozens of cancers in asymptomatic adults. Recently, two developments have driven the stock: Samsung’s strategic deal and positive trial data. These moves suggest GRAIL is gaining traction, but they also highlight the challenges ahead in turning cutting-edge science into profit.
18 October 2025
···
Sellas Life Sciences (SLS) Stock Rallies on Promising Leukemia Data – Analysts Eye Triple-Digit Upside

Sellas Life Sciences (SLS) Stock Rallies on Promising Leukemia Data – Analysts Eye Triple-Digit Upside

As of mid-October 2025, Sellas Life Sciences trades around $2.10–2.20. This is near the top of its 52-week range and about twice its price at the start of 2025 stockanalysis.com marketbeat.com. Trading volume and volatility have picked up – for instance, on Oct. 14 a massive spike in call-option activity coincided with bullish sentiment marketbeat.com. The stock’s YTD gain far outpaces many small-cap biotechs. Technical platforms note SLS is in “uptrend” territory: the stock is well above its 20-day EMA and 50-day EMA tipranks.com, which TipRanks flags as “Buy” signals. Meanwhile, about 18% of shares are sold short marketbeat.com, a high level that could fuel further swings if any surprise news hits.
18 October 2025
··
MindMed Stock Skyrockets on Psychedelic Breakthroughs – What’s Driving the MNMD Surge?

MindMed Stock Soars 15% to 52-Week High on Psychedelic Breakthrough – What’s Next for MNMD?

MindMed’s stock has been on fire, vastly outperforming the broader market in recent weeks. Shares rocketed to a 52-week high of $13.09 on October 14, closing that day at $12.58 on unusually heavy volumets2.tech. After a brief mid-week pullback on profit-takingts2.tech, MNMD roared back by week’s end – closing at $13.65 on Friday, Oct. 17, a one-day gain of +14.6%investing.com. This rally has propelled MindMed to roughly +68% YTD returnsts2.tech, a remarkable run fueled by excitement over the company’s clinical progress.
18 October 2025
··
Gilead Sciences (GILD) Stock Soars on Patent Victory, HIV Breakthroughs, and Analyst Upgrades

Gilead Sciences Stock Soars on Patent Win and HIV Breakthroughs – Will the Rally Continue?

Gilead’s stock has been on a tear in recent weeks, far outpacing the broader market. After trading in the high $110s earlier in October, GILD spiked 4.2% on Friday, Oct. 17, to close at $122.81stockanalysis.comstockanalysis.com. That rally marked a new 2025 high for the biotech stalwart and brings its year-to-date gain to roughly 45–47%ts2.tech. By comparison, the Nasdaq Biotechnology Index is up only in the single digits over the same periodts2.tech. The recent jump – adding billions to Gilead’s market cap – reflects mounting investor enthusiasm driven by a confluence of positive news. “Investors have cheered a string of positive catalysts: strong earnings, a fortified HIV franchise, and growing pipeline prospects,” TechStock² noted in an analysists2.tech.
18 October 2025
···
MindMed Stock Skyrockets on Psychedelic Breakthroughs – What’s Driving the MNMD Surge?

MindMed Stock Skyrockets on Psychedelic Breakthroughs – What’s Driving the MNMD Surge?

MindMed’s stock has been on fire in recent weeks, vastly outperforming the broader market. Shares rocketed to a 52-week high of $13.09 on October 14, closing that day at $12.58 with unusually heavy trading volumemarketbeat.com. Just a couple of weeks earlier, on September 29, MNMD spiked 12.8% in a single session, hitting ~$12.04 by day’s endallpennystocks.com. These sharp gains have propelled MindMed to roughly +68% year-to-date returnsfinance.yahoo.com, a remarkable run driven by excitement over its clinical progress.
18 October 2025
··
Gilead Sciences (GILD) Stock Soars on Patent Victory, HIV Breakthroughs, and Analyst Upgrades

Gilead Sciences (GILD) Stock Soars on Patent Victory, HIV Breakthroughs, and Analyst Upgrades

Gilead’s share price has been on a tear in recent weeks, reaching new highs for 2025. By mid-day October 17, GILD was up about 4.7% to roughly $123 per share Benzinga. Year-to-date, the stock has rallied nearly 47%, adding tens of billions to Gilead’s market value Stockanalysis. This far outpaces the single-digit gain of the Nasdaq Biotechnology Index over the same period Stockanalysis Invesco. Investors have cheered a string of positive catalysts: strong earnings, a fortified HIV franchise, and growing pipeline prospects.
17 October 2025
··
Kezar Life Sciences Stock Soars 40% After FDA Setback Sparks Strategic Shake-Up

Kezar Life Sciences Stock Soars 40% After FDA Setback Sparks Strategic Shake-Up

Kezar Life Sciences revealed a major regulatory setback for its lead drug and immediately pivoted to consider strategic alternatives. In an October 16 press release, the South San Francisco company announced it failed to reach alignment with the U.S. Food and Drug Administration on the design of a pivotal trial for zetomipzomib in autoimmune hepatitisca.investing.com. The FDA abruptly canceled a Type C meeting that was scheduled for Q4 2025 to discuss Kezar’s proposed Phase 3 trial, and instead requested a new standalone study to characterize zetomipzomib’s pharmacokinetics in patients with severe liver impairmentstocktitan.netstocktitan.net. The agency also mandated 48-hour in-patient monitoring for future trialsca.investing.com – an onerous requirement that Kezar says would likely hinder patient enrollment.
17 October 2025
··
Achieve Life Sciences Skyrockets on FDA Boost – Is This Nicotine Addiction Breakthrough a Game Changer?

Achieve Life Sciences Skyrockets on FDA Boost – Is This Nicotine Addiction Breakthrough a Game Changer?

Achieve Life Sciences stock exploded higher on the FDA news, reflecting growing optimism around cytisinicline’s prospects. In pre-market trading on Oct. 17, ACHV jumped about 22.7% after the company revealed it received a rare FDA Commissioner’s National Priority Voucher for cytisinicline’s vaping cessation indication investing.com. This rally propelled the shares to multi-month highs in the mid-$3 range. Earlier in the week, ACHV had already begun gaining momentum – on Oct. 15 the stock broke above its 200-day moving average and hit $3.19 marketbeat.com, a bullish technical signal. As of Thursday’s close, the stock was at $3.08, up roughly 10% over the past month and far outperforming the broader market investing.com.
17 October 2025
··
Biotech Breakthrough: GRAIL (GRAL) Stock Surges on New Cancer-Detection Data

GRAIL (GRAL) Rockets to Record High on Samsung Mega-Deal and Cancer Test Breakthrough

GRAIL, Inc. shares soared to record highs this week after the company announced a strategic collaboration with Samsung. On October 16, GRAIL revealed a binding agreement in which Samsung C&T and Samsung Electronics will invest $110 million into GRAIL at $70.05 per sharets2.tech. In return, Samsung C&T gains exclusive rights to distribute GRAIL’s Galleri multi-cancer early detection blood test in South Korea, with plans to expand to Japan and Singaporets2.tech. Samsung Electronics will explore technology tie-ups, integrating its digital health platforms and AI with GRAIL’s cancer-detection technologytradingview.comprnewswire.com.
17 October 2025
····
Femasys (FEMY) Rockets on Fertility Breakthroughs and FDA Milestones – What’s Behind the Surge?

Femasys (FEMY) Rockets on Fertility Breakthroughs and FDA Milestones – What’s Behind the Surge?

Femasys stock has been on a rollercoaster ride in recent sessions. As of October 17, 2025, FEMY traded around the mid-$0.70s per share – more than double its price just a few weeks prior, and well off its 52-week low near $0.31 ts2.tech. On October 16, the stock spiked dramatically: opening near $0.55, it rallied to an intraday high of $0.84 before settling at $0.745 by the close finance.yahoo.com. This explosive move came amid unusually heavy volume stockinvest.us, indicating heightened investor interest.
17 October 2025
··
Praxis (PRAX) Stock Skyrockets 180% on Game-Changing Tremor Drug Trial; Analysts See ‘Blockbuster’ Upside

Praxis (PRAX) Stock Skyrockets 180% on Game-Changing Tremor Drug Trial; Analysts See ‘Blockbuster’ Upside

Praxis Precision Medicines stock has seen a record-breaking spike in recent days after announcing landmark clinical trial results. On October 16, PRAX shares closed at $162.71, up about 183% in a single session ts2.tech ts2.tech. The stock, which had closed at $57.35 the day prior, more than tripled to reach new 52-week highs ts2.tech. Intra-day, PRAX briefly touched as high as $205 as enthusiasm peaked google.com. By midday Thursday, the company was on track to add roughly $2.7 billion to its market capitalization if gains held ts2.tech – catapulting Praxis’s valuation from around $1 billion to nearly $4 billion overnight. The explosive rally continued into Friday, Oct. 17: shares gained another ~5% in post-market and pre-market trading stocktwits.com as Wall Street’s reaction grew increasingly bullish.
17 October 2025
··
GRAIL Inc. Stock Rises on Samsung Partnership and Cancer-Test News

GRAIL Inc. Stock Rises on Samsung Partnership and Cancer-Test News

GRAIL’s shares surged after it announced a deal on Oct. 16 to partner with Samsung in Asia. The binding Letter of Intent involves Samsung C&T and Samsung Electronics investing $110 million in GRAIL at $70.05 per share, with Samsung C&T to distribute the Galleri multi-cancer screening test in South Koreainvesting.comprnewswire.com. This collaboration gives Samsung “a strong foothold for expanding into the cancer screening field”, according to Jaywoo Kim, EVP of Samsung C&Tprnewswire.com. GRAIL’s President of International Business, Sir Harpal Kumar, said the deal “strengthens our balance sheet and provides further cash runway” as the company advances toward test reimbursement globallyinvesting.comprnewswire.com. Under the LOI, definitive agreements are expected in early 2026, with testing operations to begin soon after closingprnewswire.cominvesting.com.
16 October 2025
···
Moderna’s Wild Ride: Vaccine Hopes Fuel Stock Pop Amid “One-Hit Wonder” Fears

Moderna’s Wild Ride: Vaccine Hopes Fuel Stock Pop Amid “One-Hit Wonder” Fears

Moderna’s stock is back in the spotlight after a turbulent week of news that sent the Nasdaq-listed shares swinging. On Wednesday, MRNA jumped over 5%, climbing to around $27.7 by market close marketbeat.com. The mini-rally came amid a flurry of developments – from upbeat trial data on a new cancer vaccine to analysts debating whether Moderna’s future is bright or bleak. Even after the pop, however, Moderna’s stock is a shadow of its former self: shares have cratered roughly 80% below last year’s levels marketbeat.com and are down one-third in 2025 alone. The once high-flying biotech – which briefly surpassed $170 billion in market value during the COVID vaccine euphoria – is now hovering near multi-year lows, with a market cap around $10–11 billion ts2.tech.
16 October 2025
··
Praxis Precision (PRAX) Stock Skyrockets on Game-Changing Phase 3 Results – What Experts Say

Praxis Precision (PRAX) Stock Skyrockets on Game-Changing Phase 3 Results – What Experts Say

With the stock now trading well above $150, investors are debating how much further PRAX could rise. If ulixacaltamide wins approval, analysts believe it could capture a sizable ET market. However, success in neurology trials can be binary – failures or setbacks could send the stock sharply down. Looking ahead, Praxis expects more data by late 2025/early 2026. Management’s guidance has focused on these milestones rather than concrete revenue forecasts, which is typical for clinical-stage biotechsnasdaq.com. In the near term, analysts will scrutinize FDA feedback and the actual content of the trial data. As Reuters summarized, the Phase 3 win “gives hope” for a much-needed new ET therapyreuters.com. Coupled with a healthy cash position and ongoing epilepsy trials, many experts now view Praxis’s prospects more favorably. Still, they caution that valuation is stretched – PRAX’s market cap reflects sky-high expectations that all these programs succeed. As of Oct. 16, 2025, the stock is riding a wave of bullish sentiment, but investors will want hard evidence from regulators and future studies before declaring victoryreuters.comneurologylive.com.
16 October 2025
··
Sana Biotechnology (SANA) Stock Skyrockets on ‘100-Bagger’ Hype – Experts Debate What’s Next

Sana Biotechnology (SANA) Stock Skyrockets on ‘100-Bagger’ Hype – Experts Debate What’s Next

Sana Biotechnology’s stock skyrocketed mid-week after a bold endorsement from a well-known tech investor. On Oct. 15, SANA shares jumped over 25% in a single session, closing at $5.62 ts2.tech. In intraday trading the stock even hit roughly $6.55 before paring back gains ts2.tech. The catalyst? A viral post on social media. Hedge fund manager Eric Jackson — known for spotting high-growth plays — proclaimed on X that “Biotech is back… $SANA looks like the next 100-bagger platform”. He pointed to an improving macro backdrop spurring a rotation “from megacaps to growth” stocks benzinga.com benzinga.com. Jackson’s ultra-bullish tweet injected a burst of momentum into Sana, with Benzinga reporting that the stock soared early Wednesday after his call went public ts2.tech. In fact, trading activity was so frenzied that exchanges halted SANA multiple times for volatility cooling-off periods.
16 October 2025
··
Omeros Stock Explodes 146% on Surprise $2.1B Novo Nordisk Deal – What Comes Next?

Biotech Bombshell: Omeros Stock Skyrockets on $2.1B Novo Nordisk Deal – What’s Next?

Omeros shares were trading around $4–$4.60 through early October, then exploded on Oct. 15. Data from the company’s IR site show OMER jumped from $4.10 to $10.42 by Oct 15 closeinvestor.omeros.com. Intraday on Oct 15, it even hit a high around $12.10. This roughly 150% one-day surge was driven by the Novo Nordisk deal. Trading volume was staggering: Benzinga reports ~89.2 million shares traded during the rallybenzinga.com. By mid-October 16 pre-market, OMER was around $9–10 per share – still far above levels seen just days priorts2.techbenzinga.com.
16 October 2025
···
Sana Biotech Shares Skyrocket on 100x Hype – What’s Behind the Rally?

Sana Biotech Shares Skyrocket on 100x Hype – What’s Behind the Rally?

On Oct. 15, SANA spiked as investors reacted to hedge fund manager Eric Jackson’s bullish call. In a post on X, Jackson proclaimed: “Biotech is back. Rates are falling, inflation is cooling, and money is rotating from megacaps to growth again,” and suggested “$SANA looks like the next 100-Bagger platform”benzinga.com. Benzinga and other outlets noted that this endorsement sent SANA shares up sharply that morningbenzinga.com.
15 October 2025
··
Recursion RXRX Stock Skyrockets: AI Breakthroughs and Big Pharma Deals Ignite Biotech Surge

Recursion RXRX Stock Skyrockets: AI Breakthroughs and Big Pharma Deals Ignite Biotech Surge

Recursion’s stock showed wild swings in early October. On Oct 7, 2025 the shares fell about 5.4% to ~$5.23 amid a broad market slump nasdaq.com. The very next day the stock rebounded sharply, jumping roughly 16% to ~$6.08 ts2.tech. This put RXRX near the middle of its 52-week trading range ts2.tech. Trading volume on these moves was heavy, with tens of millions of shares changing hands as investors positioned for upcoming company news. By Oct 14, RXRX was around $5.89 stocktitan.net.
15 October 2025
···
Origin Agritech’s SEED Stock Skyrockets 92% on China Seed Breakthroughs & Trade Buzz

Origin Agritech’s SEED Stock Skyrockets 92% on China Seed Breakthroughs & Trade Buzz

Origin Agritech’s stock skyrocketed this week, delivering eye-popping gains for investors. On Tuesday night, SEED shares surged over 92% in after-hours trading following a flurry of positive developmentsbenzinga.com. The price spiked from the $1.40 range to roughly $2.76 in extended trading – nearly a doubling overnight. By Wednesday Oct. 15, the stock opened sharply higher before paring back to about $1.43 by mid-dayinvesting.com, roughly flat from Tuesday’s official close of $1.44benzinga.com.
15 October 2025
·
1 … 15 16 17 18 19
Go toTop